NKT5097-101: A Phase 1, First-in-Human, Open-Label Study to Evaluate the Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of the Novel Oral Selective CDK2/4 Dual Degrader NKT5097 in Adults with Advanced/Metastatic Solid Tumors
- Title
- A Phase 1, First-in-Human, Open-Label Study to Evaluate the Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of the Novel Oral Selective CDK2/4 Dual Degrader NKT5097 in Adults with Advanced/Metastatic Solid Tumors
- Principal Investigator
- Jiang, Bei
- Phase
- I
- Age Group
- Adult
- Applicable Disease Sites
- Breast Cancer
- Other Cancers
- Participating Institutions
- Mary Babb Randolph Cancer Center
- Contacts
- Emily Hawkins, BSN
- Research Nurse
- Phone: +1 304-293-7375
- Email: eswiger1@hsc.wvu.edu